Unicycive Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Unicycive Therapeutics (UNCY).

Price Target Range — 11 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$38Upside to Avg. PT+961.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$15→$13
Aug 20, 2026	Benchmark	Bruce Jackson	PT Raise	Speculative Buy	$13→$15
Aug 13, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$37→$25
Aug 13, 2026	B. Riley Securities	Mayank Mamtani	PT Cut	Buy	$22→$20
Jul 1, 2026	Benchmark	Bruce Jackson	PT Cut	Speculative Buy	$18→$13
Jul 1, 2026	Noble Capital Markets	Robert LeBoyer	PT Cut	Outperform	$60→$50
Jun 30, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$22→$15
Jun 30, 2026	B. Riley Securities	Mayank Mamtani	Maintained	Buy	$22
Jun 2, 2026	Benchmark	Bruce Jackson	PT Raise	Speculative Buy	$15→$18
May 13, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$40→$37
Apr 6, 2026	Benchmark	Bruce D. Jackson	PT Cut	Speculative Buy	$21→$15
Apr 2, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$46→$40
Oct 29, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$9→$22
Sep 15, 2025	Benchmark	Bruce D. Jackson	PT Raise	Speculative Buy	$3→$21
May 27, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Assumes	Buy	$9
Apr 21, 2025	Guggenheim	Vamil Divan	Initiate	Buy	$6
Apr 11, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$8
Apr 1, 2025	HC Wainwright & Co.	Ed Arce	PT Raise	Buy	$4→$8
Jan 29, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$4
Jan 8, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $15 to $13.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15

Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $13 to $15.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $37 to $25.

Benzinga Newsdesk

PRO
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $20.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and lowers the price target from $18 to $13.

Benzinga Newsdesk

PRO
Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50

Noble Capital Markets analyst Robert LeBoyer maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Outperform and lowers the price target from $60 to $50.

Benzinga Newsdesk

Unicycive Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Unicycive Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15

PRO
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

PRO
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRO
Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50

People Also Watch

People Also Watch

Unicycive Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Unicycive Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

PROBenchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15

PROGuggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

PROB. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

PROBenchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRONoble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15

PRO
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

PRO
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRO
Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50